Get the Stockscreener App
16.98
0.93%
-0.16
Zenas Biopharma Inc stock is traded at $16.98, with a volume of 161.57K.
It is down -0.93% in the last 24 hours and up +1.01% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$17.14
Open:
$17.05
24h Volume:
161.57K
Relative Volume:
0.88
Market Cap:
$715.03M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.43%
1M Performance:
+1.01%
6M Performance:
+145.02%
1Y Performance:
+0.00%
1-Day Range:
$16.36
$17.33
1-Week Range:
$15.82
$18.29
52-Week Range:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
16.98 | 737.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
What MACD and RSI say about Zenas BioPharma Inc.July 2025 Retail & Technical Confirmation Trade Alerts - Newser
Real time breakdown of Zenas BioPharma Inc. stock performanceRecession Risk & Precise Buy Zone Tips - Newser
What machine learning models say about Zenas BioPharma Inc.Market Weekly Review & Weekly Stock Performance Updates - Newser
Royalty Pharma's Strategic Position in the Biopharma Royalty Space - AInvest
Is Zenas BioPharma Inc. still a buy after recent gainsWeekly Investment Report & Reliable Entry Point Trade Alerts - beatles.ru
How moving averages guide Zenas BioPharma Inc. tradingWeekly Trade Recap & Precise Trade Entry Recommendations - Newser
Chart based exit strategy for Zenas BioPharma Inc.Weekly Market Report & Weekly Top Gainers Alerts - Newser
Will Zenas BioPharma Inc. price bounce be sustainable2025 Fundamental Recap & Accurate Entry/Exit Alerts - Newser
How to integrate Zenas BioPharma Inc. into portfolio analysis toolsGap Down & Community Driven Trade Alerts - Newser
What’s the RSI of Zenas BioPharma Inc. stock2025 Geopolitical Influence & Verified Swing Trading Watchlists - khodrobank.com
Using fundamentals and technicals on Zenas BioPharma Inc.Jobs Report & Expert Curated Trade Setups - Newser
Is Zenas BioPharma Inc. stock overvalued or fairly pricedJuly 2025 Catalysts & Short-Term Swing Trade Alerts - khodrobank.com
Can Zenas BioPharma Inc. hit a new high this month2025 Market Sentiment & Risk Managed Trade Strategies - Newser
Is Zenas BioPharma Inc. trading at a discountJuly 2025 Institutional & Entry Point Confirmation Signals - khodrobank.com
Zenas Biopharma shares fall 2.28% intraday as Royalty Pharma announces $2.0 billion offering. - AInvest
Pattern recognition hints at Zenas BioPharma Inc. upside2025 Retail Activity & Weekly High Momentum Picks - Newser
Strategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial Potential - TipRanks
Trend analysis for Zenas BioPharma Inc. this weekJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
What institutional flow reveals about Zenas BioPharma Inc.2025 Earnings Surprises & Fast Momentum Entry Tips - Newser
Is Zenas BioPharma Inc. meeting your algorithmic filter criteriaQuarterly Portfolio Summary & Weekly Setup with High ROI Potential - Newser
Zenas BioPharma secures $300M funding from Royalty Pharma for obexelimab royalties. - AInvest
Published on: 2025-09-03 01:34:16 - Newser
Using data filters to optimize entry into Zenas BioPharma Inc.Portfolio Value Summary & Daily Volume Surge Signals - Newser
Wuxi XDC offers up to 22.3 million shares at HK$58.85 each - AInvest
Tick level data insight on Zenas BioPharma Inc. volatility2025 Momentum Check & Expert Curated Trade Ideas - Newser
Sasol Limited shares rise 2.89% intraday after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager - Endpoints News
Lead Plaintiff Appointed in Zenas BioPharma Class Action — Here’s How You Can Recover Your Losses - TradingView
Beone Medicines Ltd. shares rise 8.81% premarket after Royalty Pharma and Zenas BioPharma enter into a $300 million funding agreement. - AInvest
Zenas Biopharma and Royalty Pharma enter into obexelimab funding agreement for up to $300 million - MarketScreener
Zenas BioPharma, Royalty Pharma Enter $300 Million Funding Agreement for Obexelimab - MarketScreener
Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab - Nasdaq
Bolt Projects Holdings, Inc. shares rise 1.54% premarket after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Zenas BioPharma Secures $300M Funding for Obexelimab - TipRanks
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - citybiz
Zenas BioPharma, Royalty Pharma Partner for $300mln Obexelimab Funding Agreement - AInvest
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - GlobeNewswire
Royalty Pharma provides up to $300 million to Zenas BioPharma for obexelimab - StreetInsider
Zenas BioPharma Secures Up to $300 Million Funding for Obexelimab Development and Potential IgG4-RD Launch - AInvest
Zenas BioPharma, Inc. and Royalty Pharma Enter into Obexelimab Funding Agreement for Up to $300 Million - MarketScreener
Quantitative breakdown of Zenas BioPharma Inc. recent moveEarnings Risk Report & Real-Time Volume Spike Alerts - Newser
Does Zenas BioPharma Inc. show high probability of reboundWeekly Risk Report & AI Forecast Swing Trade Picks - Newser
Technical signs of recovery in Zenas BioPharma Inc.Long Setup & Real-Time Stock Entry Alerts - Newser
Will Zenas BioPharma Inc. outperform its industry peersWeekly Profit Analysis & Smart Investment Allocation Tips - khodrobank.com
Does Zenas BioPharma Inc. stock benefit from AI growthTrade Risk Report & Precise Buy Zone Tips - khodrobank.com
Can Zenas BioPharma Inc. reach all time highs this year2025 AllTime Highs & Safe Entry Trade Signal Reports - khodrobank.com
Can Zenas BioPharma Inc. deliver consistent dividendsEarnings Trend Report & Verified Entry Point Detection - khodrobank.com
Applying Elliott Wave Theory to Zenas BioPharma Inc.Trade Volume Summary & Long-Term Growth Portfolio Plans - Newser
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Zenas Biopharma Inc Stock (ZBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):